Established in 1988, Wego Group has dedicated itself to the development of medical devices and pharmaceuticals, creating a comprehensive healthcare ecosystem encompassing medical manufacturing, medical commerce, and medical services. Through relentless innovation and precise services, the company has established a strong presence in various healthcare segments, including orthopedics, blood purification, clinical care, medical packaging, surgery, medical equipment, and medical engineering.

Innovation is the cornerstone of Wego Group's growth. After over a decade of research and development, the company has successfully produced the third-generation bioresorbable coronary scaffold, becoming the first domestic enterprise to own independent intellectual property rights for bioresorbable scaffolds.

This groundbreaking scaffold gradually degrades into water and carbon dioxide within three years of implantation, allowing for complete natural absorption by the body and offering significant advantages over traditional metal scaffolds. To date, the product has been successfully applied in over 700 hospitals, helping more than 28,000 people with coronary heart disease.

Wego Group's extensive product portfolio encompasses over 1,000 varieties and 200,000 specifications of medical devices and pharmaceuticals, along with over 1,500 patents. The company has broken foreign monopolies in over 100 products, including high-end infusion consumables, orthopedic materials, prefilled syringes, indwelling needles, and blood transfusion consumables.

Wego Group's intelligent surgical robot, featured at its exhibition hall, exemplifies the company's dedication to innovation and patient care. [Photo provided to chinadaily.com.cn]

Wego Group's advanced hemodialysis equipment is showcased in its exhibition hall. [Photo provided to chinadaily.com.cn]